Search

Camostat

[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … [A198771,A198777,A193800] Camostat mesylate was first approved in Japan in January 2006.[L13197]

Bordetella pertussis pertactin antigen (formaldehyde inactivated)

Elosulfase alfa

Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.

Propylthiouracil

It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)

Vinflunine

Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. … Vinflunine ditartrate is an active ingredient in the EMA-authorised product Javlor for intravenous infusion.

Flunisolide

It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. … Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions.

Elotuzumab

Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received … Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

Betibeglogene autotemcel

[L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

Debrisoquine

An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.

Tyrothricin

Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges … and 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary) [L4019, L4021, L4022].